Anticoagulants in India: Classes, Indications & Monitoring
A clinical overview of anticoagulant India options: warfarin, heparins and DOACs, their indications, monitoring needs, and essential-medicines status.
This is a reference overview for a treating physician or hospital pharmacy committee, not a dosing guide. No anticoagulant should be started or adjusted outside individualised clinical supervision.
What are the three main anticoagulant India drug classes used today?
Warfarin remains the most widely used oral anticoagulant across Indian government and low-cost private hospitals because of its low tablet cost, despite requiring regular INR monitoring. DOACs have grown fast in urban private practice because they need no routine coagulation monitoring, at a materially higher per-tablet price.
Heparins, both unfractionated heparin and low-molecular-weight heparin (enoxaparin, dalteparin), are injectable and used mainly for acute inpatient anticoagulation, perioperative bridging, and pregnancy, where oral agents are contraindicated or impractical. All three classes appear on India's National List of Essential Medicines 2022, alongside warfarin and heparin, though DOACs are notably absent from that list (National List of Essential Medicines 2022, CDSCO).
Selection between classes turns on the clinical indication. Atrial fibrillation stroke prevention, venous thromboembolism treatment, and mechanical heart valve prophylaxis each carry different class preferences, and a mechanical valve is a setting where DOACs are specifically not recommended over warfarin.
How do DOACs actually compare with warfarin on outcomes?
Direct oral anticoagulants show efficacy at least comparable to warfarin for stroke prevention in atrial fibrillation, with a generally lower risk of intracranial bleeding across pooled trial and meta-analysis data. Warfarin needs regular INR testing and dose titration, which DOACs largely avoid.
A meta-analysis in elderly atrial fibrillation patients found DOACs at least as effective as warfarin in preventing stroke and systemic embolism, without an increase in major bleeding (comparative efficacy meta-analysis, PMC, NIH). This evidence base is now large enough that most current international guidelines favour a DOAC over warfarin for non-valvular atrial fibrillation where cost and renal function allow it.
DOACs are specifically not recommended in patients with mechanical heart valves or significant mitral stenosis, populations where warfarin remains standard of care based on trial data showing worse outcomes with DOACs in these groups. This is one of the few settings where the newer class is the wrong default, not the better one.
Why does warfarin still dominate volume in India despite the evidence?
Warfarin's tablet cost runs a small fraction of a DOAC's daily cost in most Indian retail and hospital pharmacies, which keeps it the practical default across public-sector and lower-income private care despite the monitoring burden. INR testing infrastructure, imperfect as it is, already exists at scale across Indian district and tertiary hospitals.
A patient on warfarin needs periodic INR checks, typically more frequent at initiation and tapering to monthly once stable, and dietary vitamin K consistency matters for keeping levels in range. Missed monitoring visits are the single most common reason a stable warfarin patient ends up outside therapeutic range and at real risk, in either direction.
Cost-effectiveness modelling in India-specific contexts generally favours warfarin at the population level given current DOAC pricing, while individual-patient decisions still favour a DOAC where monitoring access is poor, adherence to visits is unreliable, or the drug interaction profile of warfarin is a specific problem for that patient.
What monitoring does each class actually require?
Warfarin requires periodic INR testing with a target range set by indication, most commonly 2.0-3.0 for atrial fibrillation and venous thromboembolism, and higher for certain mechanical valves. This is the defining operational burden of the drug and the reason many patients are switched away from it once cost allows.
DOACs need no routine coagulation monitoring in most patients, but periodic renal function testing is still required since all currently marketed DOACs are renally cleared to varying degrees and dose adjustment or avoidance is needed as kidney function declines. This is frequently under-monitored in real-world practice outside specialist anticoagulation clinics.
Heparins require monitoring appropriate to the specific agent: unfractionated heparin needs activated partial thromboplastin time (aPTT) tracking during continuous infusion, while low-molecular-weight heparin generally does not, except in renal impairment, extremes of body weight, or pregnancy, where anti-Xa monitoring is used instead.
What are the real risks a clinician should track across all classes?
Bleeding is the shared, defining risk across every anticoagulant class, ranging from minor bruising to major gastrointestinal or intracranial haemorrhage, and risk scoring tools exist precisely to weigh this against the thromboembolic risk being treated. No anticoagulant decision is risk-free in either direction.
Drug and dietary interactions differ sharply by class. Warfarin interacts with a long list of drugs and with dietary vitamin K intake, while DOACs interact mainly with strong CYP3A4 or P-glycoprotein inhibitors and inducers, a narrower but still clinically significant list. Herbal supplements, particularly those with antiplatelet or hepatic-enzyme effects, are an under-recognised interaction risk with both classes.
Perioperative management, meaning when and how to hold an anticoagulant before a planned procedure and when to restart it after, is a recurring real-world failure point. Both premature discontinuation and unsafe continuation through surgery carry documented harm, and the decision belongs to the treating physician in coordination with the surgical team.
What does India's essential-medicines and access picture look like?
For anticoagulant India access specifically, warfarin and both heparin forms are listed on India's National List of Essential Medicines 2022 and are available through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana generic network at low cost, which matters directly for a patient who needs indefinite anticoagulation (PMBJP, Department of Pharmaceuticals). DOACs are not on the essential medicines list, and their retail price reflects that.
| Class | Representative agents | Routine monitoring | India essential-medicines status |
|---|---|---|---|
| Vitamin K antagonist | Warfarin | INR, periodically | Listed, NLEM 2022 |
| Injectable heparin | Unfractionated heparin, enoxaparin | aPTT (UFH) or none (LMWH) | Listed, NLEM 2022 |
| Direct oral anticoagulant | Rivaroxaban, apixaban, dabigatran | Renal function only | Not listed |
This table is a stocking and monitoring reference, not a substitute for an individualised prescribing decision.
Why does reliable in-house anticoagulant stocking matter for a hospital?
Reliable anticoagulant India stocking means a patient stabilised on a specific product, whether warfarin, a heparin bridge, or a DOAC, needs uninterrupted access to that exact formulation at the exact strength prescribed. If a hospital's in-house pharmacy runs short, the prescription walks to an outside chemist, and a therapy where missed doses carry real thromboembolic or bleeding risk becomes a continuity-of-care problem, not just a lost sale.
Our managed hospital pharmacy services guide covers how in-house stocking reliability is actually built. Our prescription leakage analysis covers what a hospital loses, clinically and financially, when it isn't. Our pharmacy inventory management guide covers the reorder discipline a narrow-therapeutic-index category like this needs.
Sources
- 1National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation
- 2Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation — National Institutes of Health, National Library of Medicine
- 3Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
- 4World Health Organization Model List of Essential Medicines — WHO
- 5NOACs Added to WHO's Essential Medicines List: Recommendations for Future Policy Actions — National Institutes of Health, National Library of Medicine
This article is for informational purposes for clinicians and hospital administrators and is not a substitute for individualised medical consultation. It contains no dosage instructions or patient-directed treatment advice.
FAQ
Frequently asked questions
Most current international guidelines favour a DOAC over warfarin for non-valvular atrial fibrillation where cost and renal function allow it, but warfarin remains standard for mechanical heart valves and significant mitral stenosis, and the choice is always an individualised physician decision.
DOACs do not need routine coagulation monitoring, but periodic renal function testing is still required because all currently marketed DOACs are cleared by the kidneys to some degree, and dose adjustment or avoidance follows declining kidney function.
Yes. Warfarin's low cost and its essential-medicines listing keep it the practical default across public-sector and cost-sensitive private care in India, alongside existing INR-testing infrastructure that DOACs don't require but that already exists at scale.
Timing depends on the specific agent, the patient's renal function, and the bleeding versus thromboembolic risk of the planned procedure, and this decision is made by the treating physician together with the surgical team, never by the patient independently.
Generic warfarin and heparin formulations are available through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana network at government-regulated low prices. DOACs are not on the essential medicines list and are not typically stocked there.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.